Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    -5.80 (-5.32%)
Bid:
103.00
Ask:
104.20
Spread: 1.20 (1.165%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Directorate Change

1 Apr 2015 08:15

RNS Number : 1252J
Synthomer PLC
01 April 2015
 

01 April 2015 

Synthomer plc

Appointment of Chief Financial Officer

Synthomer plc ('Synthomer' or 'the Company') announces that it has appointed Steve Bennett as its Chief Financial Officer. Steve will join Synthomer in July and will succeed David Blackwood, who announced in December that he would step down from the role after seven years. David will leave the Company after a brief handover period.

Steve joins from INEOS Group ('INEOS') where he has been Chief Financial Officer at Petroineos Refining Limited, a JV between INEOS Group AG and PetroChina, since 2006. In addition to this role, he has acted as Chief Financial Officer of INEOS Upstream Limited, a start-up oil and gas exploration business, and of INEOS Olefins and Polymers South and INEOS Phenol.

Steve joined Coopers & Lybrand in 1986 and is a qualified Chartered Accountant. He joined Full Circle Industries plc as Company Secretary and Group Controller before moving to PricewaterhouseCoopers ('PWC') in 1997 as a Director in Transaction Services. At PWC, he specialised in public and private equity transactions across a variety of sectors including chemicals.

Neil Johnson, Chairman, said:

"I am delighted to welcome Steve to Synthomer. He has a superb track record at INEOS and thirty years of experience working in finance across a broad range of sectors, not least the chemical industry. I have no doubt that Steve's considerable knowledge and skills will be invaluable to the Group as we move forward.

On behalf of the Board, I would once again like to thank David for his seven years of service. His contribution has been instrumental in helping Synthomer through a significant transformation and we wish him all the best for the future."

Calum MacLean, Chief Executive, said:

"I have known Steve for the past ten years and I am delighted to welcome someone of his calibre to Synthomer. His significant experience will be of enormous benefit to me and the senior team as we look to take Synthomer into a new phase of its growth."

There are no further details required to be disclosed under LR 9.6.13R of the Listing Rules of the UK Listing Authority.

-ENDS-

Enquiries:

Synthomer plcNeil Johnson, ChairmanCalum MacLean, Group Chief Executive

 

+ 44 (0) 1279 436 211

Pendomer Charles Armitstead

+44 (0) 20 3603 5220

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUAABRVSASRRR
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.